Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94

Clin Diagn Lab Immunol. 2001 Nov;8(6):1279-81. doi: 10.1128/CDLI.8.6.1279-1281.2001.

Abstract

The average 50% inhibitory concentration (IC(50)) values for AD169 were 0.22 +/- 0.09 microM 1263W94 and 5.36 +/- 0.12 microM ganciclovir. For 35 human cytomegalovirus (HCMV) clinical isolates the average IC(50) was 0.42 +/- 0.09 microM 1263W94, and for 26 ganciclovir-susceptible HCMV clinical isolates the average IC(50) was 3.78 +/- 1.62 microM ganciclovir. Nine HCMV clinical isolates that were resistant to ganciclovir were completely susceptible to 1263W94.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Antiviral Agents / pharmacology*
  • Benzimidazoles / pharmacology*
  • Cytomegalovirus / drug effects*
  • Cytomegalovirus / genetics
  • DNA, Viral / analysis
  • Fibroblasts / virology
  • Flow Cytometry
  • Ganciclovir / pharmacology*
  • Humans
  • Inhibitory Concentration 50
  • Nucleic Acid Hybridization
  • Ribonucleosides / pharmacology*
  • Viral Plaque Assay

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • Benzimidazoles
  • DNA, Viral
  • Ribonucleosides
  • Ganciclovir
  • maribavir